liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Long-Term Effects of Irbesartan and Atenolol on the Renin-Angiotensin-Aldosterone System in Human Primary Hypertension: The Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)
Division of Internal Medicine, Karolinska Inst. Danderyd Hospital, Stockholm, Sweden.
Linköping University, Department of Medicine and Care, Internal Medicine. Linköping University, Faculty of Health Sciences. AstraZeneca Research & Development, Mölndal, Sweden.
AstraZeneca Research and Development, Mölndal, Sweden, Department of Medical Sciences, University Hospital, Uppsala, Sweden.
Linköping University, Department of Medicine and Care, Internal Medicine. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Centre for Medicine, Department of Endocrinology and Gastroenterology UHL.ORCID iD: 0000-0002-1680-1000
Show others and affiliations
2003 (English)In: Journal of Cardiovascular Pharmacology, ISSN 0160-2446, E-ISSN 1533-4023, Vol. 42, no 6, 719-726 p.Article in journal (Refereed) Published
Abstract [en]

We examined long-term influence of the angiotensin II type 1-receptor blocker irbesartan and the beta1-adrenergic receptor blocker atenolol on some neurohormonal systems implicated in the pathophysiology of cardiac hypertrophy. Thus, 115 hypertensive patients with left ventricular hypertrophy were randomized to receive double-blind irbesartan or atenolol, with additional therapy if needed. Neurohormone measurements and echocardiography were performed at weeks 0, 12, 24, and 48. Left ventricular mass was reduced more by irbesartan than by atenolol (-26 g/m2 versus -14 g/m2, P = 0.024), despite similar reductions in blood pressure. Plasma renin activity and angiotensin II increased (P < 0.001) by irbesartan (0.9 ± 0.7 to 3.4 ± 4.2 ng/mL × h, and 3.0 ± 1.6 to 13.0 ± 17.7 pmol/L), but decreased (P < 0.01) by atenolol (1.0 ± 0.6 to 0.7 ± 0.6 ng/mL × h, and 3.4 ± 1.6 to 3.2 ± 2.2 pmol/L). Serum aldosterone decreased (P < 0.05) by both irbesartan (346 ± 140 to 325 ± 87 pmol/L) and atenolol (315 ± 115 to 283 ± 77 pmol/L). Changes in left ventricular mass by irbesartan related inversely to changes in plasma renin activity, angiotensin II, and aldosterone (all P < 0.05). Plasma levels and 24-hour urinary excretions of catecholamines, plasma leptin, proinsulin, insulin and insulin sensitivity remained largely unchanged in both groups. Thus, the renin-angiotensin aldosterone system appears to be an important non-hemodynamic factor in the regulation of left ventricular mass.

Place, publisher, year, edition, pages
Lippincott Williams & Wilkins, 2003. Vol. 42, no 6, 719-726 p.
Keyword [en]
Aldosterone, Angiotensin II, Insulin, Left ventricular hypertrophy, Norepinephrine, Renin
National Category
Cardiac and Cardiovascular Systems Pharmacology and Toxicology
URN: urn:nbn:se:liu:diva-46411DOI: 10.1097/00005344-200312000-00005ISI: 000186815600005OAI: diva2:267307
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2014-11-18Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Öhman, K. PeterNyström, Fredrik
By organisation
Internal MedicineFaculty of Health SciencesDepartment of Endocrinology and Gastroenterology UHL
In the same journal
Journal of Cardiovascular Pharmacology
Cardiac and Cardiovascular SystemsPharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 35 hits
ReferencesLink to record
Permanent link

Direct link